R&D Trends

Chiromics, GSK enter into collaboration

Monday, November 19, 2012 12:09 PM

Chiromics, a drug discovery company, has formed a collaboration with global healthcare company GlaxoSmithKline to discover novel classes of small molecules against certain biological targets.

More... »

Factor Bioscience awarded two NIH grants for Alzheimer's research

Monday, November 19, 2012 11:12 AM

The National Institutes of Health, through the National Center for Advancing Translational Sciences, has awarded Factor Bioscience, a developer of cell-based therapeutics and research tools, two Small Business Innovation Research (SBIR) grants to accelerate the development of new treatments for Alzheimer's disease.

More... »

Sanofi, T1D Exchange to investigate optimal care for young people with diabetes

Friday, November 16, 2012 02:06 PM

Sanofi, a global healthcare comapny, and T1D Exchange, a non-profit organization focused on type 1 diabetes, will collaborate on the TEENs registry study, which aims to provide the type 1 diabetes community with a better understanding of how children, adolescents and young adults are currently living with type 1 diabetes, and to deliver recommendations for better disease management and patients outcomes.

More... »

New report shows more than 220 drugs in pipeline for diabetes

Thursday, November 15, 2012 08:00 AM

America's biopharmaceutical research companies currently are developing 221 innovative new medicines to help the nearly 26 million patients in the U.S. affected by diabetes.

More... »

Forest Labs, Adamas to develop fixed dose combo of Namenda XR and Donepezil for Alzheimer's

Wednesday, November 14, 2012 02:45 PM

Forest Laboratories, an international pharmaceutical company, and Adamas Pharmaceuticals, an Emeryville, Calif.-based therapeutics company focused on CNS disorders, have entered into an agreement for the development and commercialization of a fixed dosed combination (FDC) of Namenda XR (memantine HCl extended release) and donepezil HCl as a once daily therapy for the treatment of moderate to severe dementia of the Alzheimer's type in the U.S.

More... »

GNS Healthcare, Dana-Farber, Mount Sinai to build computer model of multiple myeloma

Tuesday, November 13, 2012 01:57 PM

GNS Healthcare, a healthcare data analytics company, has entered into a collaboration with Dana-Farber Cancer Institute and the Mount Sinai School of Medicine to create a data-driven computer model of multiple myeloma, the second most common blood cancer in the U.S.

More... »

Foundation Medicine, AstraZeneca collaborate on genomic profiling for targeted cancer therapies

Tuesday, November 13, 2012 09:23 AM

Foundation Medicine, a molecular information company based in Cambridge, Mass., has formed a multi-year collaboration with global biopharmaceutical company AstraZeneca to identify alterations found in cancer-related tumor genes that may predict a person's response or resistance to targeted medicines.

More... »

Northwest Bio collaborates with U.K. cancer institutions for DCVaxR-Direct trial

Wednesday, November 7, 2012 11:51 AM

Northwest Biotherapeutics, a Bethesda, Md.-based biotechnology company developing DCVax personalized immune therapies for cancer, has initiated a collaboration with U.K.-based cancer institutions Sarah Cannon Research U.K. and Leaders in Oncology Care (LOC) on a phase I/II trial with DCVax-Direct for metastatic colon cancer. 

More... »

U.K. government awards $2.7M grant to PsiOxus cancer vaccine

Wednesday, November 7, 2012 10:57 AM

PsiOxus Therapeutics, a development stage biotechnology company based in the U.K was awarded a $2.7 million grant from the U.K. government-backed Biomedical Catalyst to initiate a phase I/II clinical trial to assess the use of ColoAd1 in the treatment of platinum-resistant, recurrent ovarian cancer.

More... »

Curie-Cancer, Harmonic to explore anti-cancer activity of several compounds

Monday, November 5, 2012 03:21 PM

Curie-Cancer, the body responsible for developing Institut Curie’s industry partnership activities, and Harmonic Pharma, a French company focused on extending the therapeutic application of compounds already on the market, have entered into a research collaboration aimed at exploring the anti-cancer activity of several molecules in Harmonic’s portfolio.

More... »